Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: flickerful who wrote (4940)	8/14/1998 10:45:00 AM
From: Nemer	Read Replies (1) \| Respond to of 9523

Randy: Just an observation as to the sale of Howmedicia ...... PFE is well aware of The Street and it's reaction to EPS .... the entire section which PFE has been selling off and endeavoring to sell off more of is at the bottom end of earnings contribution to the company. So I think that the disposition of the money received from this sale is of secondary importance to the stock price but will have much more import in the elimination of a much lesser profit producer than the core pharma base. Monsanto is a good example, albeit more extreme, of selling or spinoff of a portion of corporate assets. MTC, with the spinoff of Solutia SOI, changed it's EPS radically. Different areas of operation have vastly differing profits and sometimes are as difficult to evaluate as apples and oranges . I know that most on the thread already know this, and indeed it might have already been posted ( I don't read all posts here) , but I thought it needed to be considered in the light of the latest asset sale. Regards ---- Nemer